Pharmafile Logo

Ocrevus

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

Roche Basel Switzerland

Roche plans to launch rapid COVID-19 antigen test later this month

Swiss pharma also intends to file for emergency approval in the US

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

Roche Basel Switzerland

Roche’s Soliris rival Enspryng bags FDA approval

Drug is second to be approved for the treatment of NMOSD

- PMLiVE

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Data from the trial has been published in the New England Journal of Medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links